Podcasts about Prostate cancer screening

NBA legend and Miami Heat icon Alonzo Mourning joins Baptist Health primary care physician Dr. Daniel Ramon for a powerful conversation about men's health, preventive screenings and why feeling fine does not always mean being healthy.During this special Men's Health Month discussion, Mourning opens up about his kidney transplant, prostate cancer diagnosis and heart procedures — including the routine checkup that led doctors to discover a serious heart rhythm issue even though he felt completely fine.Together, Mourning and Dr. Ramon encourage men to take charge of their health, schedule regular checkups, ask questions, know their family history and stop waiting until something hurts before seeing a doctor.Because as Mourning says: “If you don't go, you don't know.”For more health and wellness resources, visit Baptist Health South Florida's Resource Blog: https://baptisthealth.net/newsGuests:Alonzo MourningMiami HEAT Alumni, NBA Hall of FamerProstate Cancer SurvivorDaniel Ramon, M.D.Family Medicine PhysicianBaptist Health Primary CareIf you found this episode helpful, you may also enjoy:The Screening That Changed Everything for Alonzo MourningChampioning Men's Health: A Conversation with Alonzo MourningThe Conversation Men Need to Have and Why It Starts Now

Kevin Boston-Hill speaks with Naismith Basketball Hall of Famer Nancy Lieberman, and Chief Philanthropy Officer of the Prostate Cancer Foundation, Lori Tessel, about how important it is to have prostate cancer screening. Those who get screened and detect the cancer early have a 99% survival rate.

Join Dr. Jill Valerius and host Lee Henrikson as they continue to discuss vaping dangers and begin a discussion on prostate cancer screening.

A lot of Christian men treat fitness and health like optional side quests—something nice to care about after the important stuff is handled. But what if stewarding your body is actually part of your calling as a husband, father, and leader? Right behind spiritual and relational capital sits physical capital, and ignoring it eventually impacts everything else God has entrusted to you. In this episode, we talk honestly about the “dad bod” mindset, why physical health matters more than most Christian men want to admit, and some practical ways to start taking stewardship of your body seriously. Steven shares the conversation with his doctor that changed everything for him, and together we unpack how better health can help you show up stronger for your wife, your kids, and the work God has given you. Links in this Episode AW Bootcamp: Aug 21-23 https://abrahamswallet.com/retreat/ https://www.walkinlab.com https://www.loseit.com https://www.myfitnesspal.com https://www.whoop.com https://www.stelo.com https://open.spotify.com/track/3iiMf4CK7te9bzc8F20Lkk?si=MTsGPWz2S92F3FYxRBf0aA Please partner with us in inspiring and equipping multi-gen families at https://abrahamswallet.com/support AW website Apple Podcasts Spotify YouTube Facebook LinkedIn Instagram Chapters (00:00:00) - 7 Rules For Being a Biblical Boss(00:00:26) - Abraham's Wallet Family Retreat Boot Camp(00:02:16) - Dr. Lacroix(00:04:09) - Abe's Wallet: The Doctor's Advice(00:08:56) - The 5 Capitals of Life(00:10:15) - Should Your Body Be Embarrassed?(00:15:32) - Physical Capital(00:22:25) - Are You Active?(00:23:44) - Top 10 Health Tips For Guys(00:29:28) - How to Stop Eating Junk Food and Lose Weight(00:36:27) - Prostate Cancer Screening for Men at 50(00:40:23) - How to Sleep Better(00:47:17) - How to Manage Your Body's Health(00:50:06) - One Week Challenge for Physical Capital(00:53:26) - New Kind of Man

Police apologise for arresting a dying teen, stabbed with a ceremonial knife, after his killer's 'wicked' racism lie. Dame Helen Mirren is verbally abused in the street by a pro-Palestinian activist and Health officials reject calls for mass screening for prostate cancer by rationing it to only "a few thousand" men.

In this episode of the Clinical Update podcast, MIMS Learning deputy editor Rhiannon and medical editor Dawn provide a comprehensive update on prostate health. High-profile figures, such as Sir Chris Hoy, opening up about their own diagnoses have significantly increased public awareness of prostate cancer. In light of this, the editors discuss the rationale for targeted prostate cancer screening and patient counselling around prostate-specific antigen (PSA) tests. The conversation also highlights health inequalities in prostate cancer diagnosis, noting that Black men have double the risk of prostate cancer compared with other groups, and highlighting care for trans women, who may remain at risk of prostate cancer after gender-confirming surgery.Beyond malignancy, this episode covers the symptoms and management of benign prostatic hyperplasia (BPH) and chronic prostatitis in primary care.Educational objectivesAfter listening to this podcast, healthcare professionals should be better able to:Recall draft recommendations for targeted prostate cancer screening in high-risk groupsIdentify key risk factors for prostate cancer, including ethnicity and ageOutline factors that can raise or suppress PSA levelsUnderstand the diagnostic pathway and the role of digital rectal examinationRecognise symptoms and potential complications of BPH and prostatitisYou can access the website version of this podcast, along with a list of key learning points, on MIMS Learning - and make notes for your appraisal. MIMS Learning offers hundreds of hours of CPD for healthcare professionals, along with a handy CPD organiser.Please note: this podcast is presented by medical editors and discusses educational content written or presented by doctors, nurses and other healthcare professionals on the MIMS Learning website and at live events.This episode was produced by Jude Owen.MIMS LearningRegister for a FREE accountExpert perspective: prostate cancer diagnosisGuidance update: NICE guidelines on prostate cancerLatest updates in prostate cancer for primary careBenign prostatic hyperplasia: clinical reviewProstate Cancer UK Hosted on Acast. See acast.com/privacy for more information.

Advocates for people with prostate cancer want men to speak up about the need for a national screening programme. Prostate Cancer Foundation president Danny Bedingfield spoke to Ingrid Hipkiss.

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this episode, Peter takes a deep dive into prostate cancer screening, explaining why advanced and metastatic diagnoses continue to rise despite the availability of screening tools, and what can be done to reverse this trend. He breaks down what PSA actually measures and why it is far more informative when tracked over time rather than interpreted as a single value, and he explores how tools like MRI, PSA density, PSA velocity, and improved biopsy techniques can both reduce unnecessary procedures and improve the detection of aggressive cancers. Peter also discusses the role of active surveillance in avoiding overtreatment for low-risk cases, examines the flawed evidence that has historically been used to argue against PSA screening, and highlights how medications like finasteride can suppress PSA levels and potentially mask warning signs if not properly accounted for. Ultimately, he makes a compelling case for the importance of regular PSA testing as a key strategy in the effort to eliminate prostate cancer mortality. We discuss: The failure of current prostate cancer screening guidelines, and the rise in advanced disease despite available tools [2:30]; PSA screening fundamentals: benefits, harms, and the guideline shift driven by overdiagnosis concerns [5:30]; The impact of reduced PSA screening: rising rates of late-stage prostate cancer and worsening population-level outcomes [12:00]; How modern screening practices use PSA trends, MRI, and new imaging advances to improve accuracy and reduce unnecessary procedures [15:00]; Advances in prostate biopsy: transperineal approach improves safety and cancer detection [23:00]; Reducing overtreatment: Gleason scoring and active surveillance in modern prostate cancer care [25:30]; Reevaluating PSA screening guidelines: how flaws in the PLCO trial undermine the evidence used to argue against PSA screening [29:45]; Prostate cancer screening today: improved tools, flawed guidelines, and preventable mortality [33:45]; How finasteride and similar drugs suppress PSA levels and can lead to missed or delayed prostate cancer diagnoses if not properly accounted for [38:00]; The optimistic future of prostate cancer: modern screening advances and the potential to reduce mortality [43:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

Better health outcomes often come from slowing down and asking a harder question: is this test actually serving me, or is it serving the system?In this episode, Dr. Stephen Petteruti talks through the reality behind prostate cancer screening—what's driving it, who's funding it, and where the standard approach falls short. He explains how free PSA screenings are often backed by pharmaceutical companies, why the commonly used PSA cutoff of 4 is an arbitrary number that creates unnecessary fear, and how the medical system can capitalize on men's anxiety around a cancer diagnosis. He walks through what a normal PSA trajectory looks like decade by decade, why the prostate rectal exam has been clinically invalidated, and how to interpret MRI results and PI-RADS scores without getting swept into reactive decision-making.Dr. Stephen offers a grounded way to think about it: understand your numbers in context, question every recommendation, and recognize that prostate cancer—for the vast majority of men—is something you live with, not something that kills you. The goal is to slow down, protect yourself from iatrogenic harm, and make decisions based on information rather than fear.The bigger message is simple and practical. Long-term prostate health is built through informed decision-making, not reactive testing. Screening still has a role, but it should be understood in context—not accepted on autopilot.If you're a man over 40 or you care about someone who is, spend a few minutes with this episode. Tune in now: Your Free Prostate Cancer Screening Is a Trap — Here Is the Truth.Enjoy the podcast? Subscribe and leave a 5-star review on your favorite platforms.Dr. Stephen Petteruti is a board-certified physician specializing in longevity-focused, integrative medicine. He works with men navigating prostate cancer, testosterone and hormone health, aging, and performance using proactive, evidence-informed strategies grounded in real clinical practice. His approach prioritizes preserving function, strength, and quality of life while helping patients make clear, informed decisions beyond reactive, fear-driven care.Learn more: https://www.drstephenpetteruti.com/Learn more: https://www.intellectualmedicine.com/Connect with Dr. Petteruti on:⁠Instagram: ⁠https://www.instagram.com/dr.stephenpetteruti/⁠Facebook: ⁠https://www.facebook.com/dr.stephenpetteruti⁠Subscribe to Intellectual Medicine on:Apple Podcast: https://tinyurl.com/DrPetterutiApplePodcastSpotify: https://tinyurl.com/DrPetterutiSpotifyPodcastDisclaimer:The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.Produced by https://www.BroadcastYourAuthority.com

If your erections are changing, it may not be “just aging.” Rita De Michele sits down with Dr Arthur Burnett II, a Johns Hopkins urologist whose research helped make treatments like Viagra possible, to explain why erectile dysfunction can be an early signal of bigger health issues like cardiovascular disease and diabetes. They also unpack common testosterone misconceptions, when men should ask for PSA screening, and how modern prostate cancer care can protect long term sexual function. This is a practical, straight talking conversation to help men advocate for their health earlier, not later.

"The thought of recurrence is also a psychosocial issue for our patients. They're being monitored very closely for five years, so there's always that thought in the back of their head, 'What if the cancer comes back? What are the next steps? What am I going to do next?' It's really important that we have conversations with patients and their families about where they're at, what we're looking for, and reassure them that we'll be with them during this journey and help them through whatever next steps happen," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer survivorship considerations for nurses. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by December 19, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to survivorship nursing considerations for people with prostate cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 390: Prostate Cancer Treatment Considerations for Nurses Episode 387: Prostate Cancer Screening, Early Detection, and Disparities Episode 201: Which Survivorship Care Model Is Right for Your Patient? Episode 194: Sex Is a Component of Patient-Centered Care ONS Voice articles: APRNs Collaborate With PCPs on Shared Survivorship Care Models Exercise Before ADT Treatment Reduces Rate of Side Effects Frank Conversations Enhance Sexual and Reproductive Health Support During Cancer Here Are the Current Nutrition and Physical Activity Recommendations for Cancer Survivors Nursing Considerations for Prostate Cancer Survivorship Care Regular Physical Activity and Healthy Diet Lower Risk of All-Cause and Cardiac Mortality in Prostate Cancer Survivors Sexual Considerations for Patients With Cancer Sleep Disturbance Is Part of a Behavioral Symptom Cluster in Prostate Cancer Survivors ONS course: Essentials in Survivorship Care for the Advanced Practice Provider Clinical Journal of Oncology Nursing articles: A Patient-Specific, Goal-Oriented Exercise Algorithm for Men Receiving Androgen Deprivation Therapy Incorporating Nurse Navigation to Improve Cancer Survivorship Care Plan Delivery Prostate Cancer: Survivorship Care Case Study, Care Plan, and Commentaries The Role of the Advanced Practice Provider in Bone Health Management for the Prostate Cancer Population Oncology Nursing Forum articles: A Qualitative Exploration of Prostate Cancer Survivors Experiencing Psychological Distress: Loss of Self, Function, Connection, and Control Identification of Symptom Profiles in Prostate Cancer Survivors Sleep Hygiene Education, ReadiWatch™ Actigraphy, and Telehealth Cognitive Behavioral Training for Insomnia for People With Prostate Cancer Understanding Men's Experiences With Prostate Cancer Stigma: A Qualitative Study Other ONS resources: Late Effects of Cancer Treatment Huddle Card Survivorship Care Plan Huddle Card Survivorship Learning Library American Cancer Society (ACS): Living as a Prostate Cancer Survivor ACS prostate cancer survivorship studies To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Some of the most common late side effects [are] urinary, bowel, and sexual dysfunction issues. For urinary effects, it can include urgency and frequency, some incontinence, or a weak or slow urine stream that frequently bothers the patient after treatment. Bowel effects can happen such as constipation, diarrhea, or inflammation of the rectum, which can lead to bleeding or mucus discharge. And then erectile dysfunction is another side effect that patients with prostate cancer often deal with and have to work with their physicians on, depending on what they want with that function. Fatigue, lymphedema, and skin changes can also occur after treatment." TS 1:40 "If we can catch [prostate cancer] and take care of it at an early stage, overall survival is about 90%. If the disease is localized, it's 99%. If we can take out the prostate, radiate the prostate, we can do something with that—localized, 99% survival rate. If there's regional metastasis, it's about 90%. And if there's distant metastasis, it's about 30% survival." TS 3:55 "Prostate cancer recurs in about 20%–30% of patients within the first five years of initial treatment. ... There's not a lot of research out there that shows what can reduce risk, but what has been shown to be effective is regular exercise, quitting smoking, and eating a healthy diet. ... It's really important for our patients to understand the importance of having follow-up visits so that we can catch a recurrence quickly instead of waiting years down the road. Prostate cancer is usually a slow-growing disease, so if we can pick it up quickly in those revisits, we can start another treatment for the patient." TS 6:00 "Sexuality is not something many people are comfortable discussing, but we really need to talk with patients and let them know that this is normal. It is normal that you may have some sexual dysfunction. It's normal that you may not feel the way you did before. Talk to us about it, let us know where you're at, let us know what your goals are, because there are a lot of things we can do. There are medications we can use for impedance. There are devices and implants available to help the patient to support them and give them whatever their goal is for their sexuality." TS 9:41 "Providing survivorship care plans are important for these patients—something that can be sent off to everyone else that's caring for that patient. You have your primary care physician, urologist, oncologist, the oncology nurse, maybe a navigator, and [others] who are looking into this patient. So, giving that patient a survivor care plan and putting it with their files to include a summary of the treatment received, because most of the time a patient is not going to remember exactly what they received. A suggested schedule for follow-up exams—so again, if a primary care provider is not used to dealing with a patient with prostate cancer, they have something to go off of. A schedule of other tests they may need in the future including screening for other types of cancer. Are they a smoker? Do they need lung screening? Do they need any other screenings related to types of cancers? And then a list of possible late or long-term side effects." TS 15:16 "I think a lot of people know about the long-term sexual effects, but what we don't really talk about is the effect that it has on the patient's self-image. How they define themselves, how they look, their body image, their self-image. It's really important that we continue to discuss it with patients and make them comfortable when discussing their sexuality and their goals for sexuality. They may be having these self-image issues after treatment that they're just not telling us about and that can affect their quality of life." TS 18:38

Brian Crombie is joined by Dr. Anna Wilkinson, a family physician with a special interest in oncology and an Associate Professor at the University of Ottawa, for a timely and evidence-based conversation about prostate cancer screening — and why current approaches may need to change. Dr. Wilkinson bridges primary care and oncology, studying how screening guidelines translate into real-world outcomes. In this episode, she explains why prostate cancer screening today looks very different than it did decades ago, and why outdated assumptions may be contributing to rising rates of advanced, incurable disease.Topics discussed include:

YCCI Cultural Ambassador Community Health Watch- Importance of Prostate Cancer Screening by WNHH Community Radio

In this week's Talking Health, Jessica is joined by Professor of Urology Stephen Langley to discuss the National Screening Committee recommendation for a UK-wide prostate screening programme for men aged over 45, which was not passed in November 2025.

On this week's news podcast, the former UK prime minister, David Cameron, calls for prostate cancer screening following his diagnosis. But does it really help to know you have the disease? Also, we find out about the DNA composition of the carbon-rich asteroid Bennu, the underlying cause of Santorini's recent earthquakes, and scientists discover where domestic cats came from... Like this podcast? Please help us by supporting the Naked Scientists

"Any time the patient hears the word 'cancer,' they shut down a little bit, right? They may not hear everything that the oncologist or urologist, or whoever is talking to them about their treatment options, is saying. The oncology nurse is a great person to sit down with the patient and go over the information with them at a level they can understand a little bit more. To go over all the treatment options presented by the physician, and again, make sure that we understand their goals of care," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer treatment considerations for nurses.  Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by November 21, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the treatment of prostate cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 387: Prostate Cancer Screening, Early Detection, and Disparities Episode 373: Biomarker Testing in Prostate Cancer Episode 324: Pharmacology 101: LHRH Antagonists and Agonists Episode 321: Pharmacology 101: CYP17 Inhibitors Episode 208: How to Have Fertility Preservation Conversations With Your Patients Episode 194: Sex Is a Component of Patient-Centered Care ONS Voice articles: Communication Models Help Nurses Confidently Address Sexual Concerns in Patients With Cancer Exercise Before ADT Treatment Reduces Rate of Side Effects Frank Conversations Enhance Sexual and Reproductive Health Support During Cancer Nurses Are Key to Patients Navigating Genitourinary Cancers Sexual Considerations for Patients With Cancer The Case of the Genomics-Guided Care for Prostate Cancer ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (Second Edition) Manual for Radiation Oncology Nursing Practice and Education (Fifth Edition) Clinical Journal of Oncology Nursing articles: Brachytherapy: Increased Use in Patients With Intermediate- and High-Risk Prostate Cancers Physical Activity: A Feasibility Study on Exercise in Men Newly Diagnosed With Prostate Cancer The Role of the Advanced Practice Provider in Bone Health Management for the Prostate Cancer Population Oncology Nursing Forum articles: An Exploratory Study of Cognitive Function and Central Adiposity in Men Receiving Androgen Deprivation Therapy for Prostate Cancer ONS Guidelines™ for Cancer Treatment–Related Hot Flashes in Women With Breast Cancer and Men With Prostate Cancer Other ONS resources: Biomarker Database (refine by prostate cancer) Biomarker Testing in Prostate Cancer: The Role of the Oncology Nurse Brachytherapy Huddle Card External Beam Radiation Huddle Card Hormone Therapy Huddle Card Luteinizing Hormone-Releasing Hormone Antagonist Huddle Card Sexuality Huddle Card American Cancer Society prostate cancer page National Comprehensive Cancer Network homepage To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "I think it's important to note that urologists are usually the ones that are doing the diagnosis of prostate cancer and really start that staging of prostate cancer. And the medical oncologists usually are not consulted until the patient is at a greater stage of prostate cancer. I find that it's important to state because a lot of our patients start with urologists, and by the time they've come to us, they're a lot further staged. But once a prostate cancer has been suspected, the patient needs to be staged for the extent of disease prior to that physician making any treatment recommendations. The staging includes doing a core biopsy of the prostate gland. During this core biopsy, they take multiple different cores at different areas throughout the prostate to really look to see what the cancer looks like." TS 1:46 "[For] the very low- and low-risk group, the most common [treatment] is active surveillance. ... Patients can be offered other options such as radiation therapy or surgery if they're not happy with active surveillance. ... The intermediate-risk group has favorable and unfavorable [status]. So, if they're a favorable, their Gleason score is usually a bit lower, things are not as advanced. These patients are offered active surveillance and then either radical prostatectomy with possible removal of lymph nodes or radiation—external beam or brachytherapy. If a patient has unfavorable intermediate risk, they are offered radical prostatectomy with removal of lymph nodes, external radiation therapy plus hormone therapy, or external radiation with brachytherapy. All three of these are offered to patients, although most frequently we see that our patients are taken in for radical prostatectomy. For the high- or very high-risk [group], patients are offered radiation therapy with hormone therapy, typically for one to three years. And then radical prostatectomy with removal of lymph nodes could also be offered for those patients." TS 7:55 "Radiation can play a role in any risk group depending on the patient's preference. ... The types of radiation that we use are external beam, brachytherapy, which is an internal therapy, and radiopharmaceuticals, [which are] more for advanced cancer, but we are seeing them used in prostate [cancer] as well. External beam radiation focuses on the tumor and any metastasis we may have with the tumor. It can be used in any risk [group] and for recurrence if radiation has not been done previously. If a patient has already been radiated to the pelvic area or to the prostate, radiation is usually not given again because we don't want to damage the patient any further. Brachytherapy is when we put radioactive pellets directly into the prostate. For early-stage prostate cancer, this can be given alone. And for patients who have a higher risk of the cancer growing outside the prostate, it can be given in combination with external beam radiation. It's important to note with brachytherapy, it cannot be used on patients who've had a transurethral resection of the prostate or any urinary problems. And if the patient has a large prostate, they may have to be on some hormone therapy prior to brachytherapy, just to shrink that prostate down a little bit to get the best effect. ... Radiopharmaceuticals treat the prostate-specific membrane antigen." TS 11:05 "The side effects of surgery are usually what deter the patient from wanting surgery. The first one is urinary incontinence. A lot of times, a patient has a lot of urinary incontinence after they have surgery. The other one is erectile dysfunction. A lot of patients may not want to have erectile dysfunction. Or, if having an erection is important to the patient, they may not want to have surgery to damage that. In this day and age, physicians have gotten a lot better at doing nerve-sparing surgeries. And so they really do try to do that so that the patient does not have any issues with erectile dysfunction after surgery. But [depending on] the extent of the cancer where it's growing around those nerves or there are other things going on, they may not be able to save those nerves." TS 15:26 "Luteinizing hormone-releasing hormone, or LHRH antagonists or analogs, lower the amount of testosterone made by the testicles. We're trying to stop those hormones from growing to prevent the cancer. ... When we lower the testosterone very quickly, there can be a lot more side effects. But if we lower it a little bit less, we can maybe help prevent some of them. The side effects are important. When I was writing this up, I was thinking, 'Okay, this is basically what women go through when they go through menopause.' We're decreasing the estrogen. We're now decreasing the testosterone. So, the patients can have reduced or absent sexual desire, they can have gynecomastia, hot flashes, osteopenia, anemia, decreased mental sharpness, loss of muscle mass, weight gain, and fatigue." TS 17:50 "What we all need to remember is that no patient is the same. They may not have the same goals for treatment as the physicians or the nurses want for the patient. We talked about surgery as the most common treatment modality that's presented to patients, but it's not necessarily the option that they want. It's really important for healthcare professionals to understand their biases before talking to the patients and the family. It's also important to remember that not all patients are in heterosexual relationships, so we need to explain recovery after treatment to meet the needs of our patients and their sexual relationships, which is sometimes hard for us. But remembering that—especially gay men—they may not have the same recovery period as a heterosexual male when it comes to sexual relationships. So, making sure that we have those frank conversations with our patients and really check our biases prior to going in and talking with them." TS 27:16

European Study of Prostate Cancer Screening — 23-Year Follow-upAssociation Between Baseline Diastolic Blood Pressure and the Efficacy of Intensive vs Standard Blood Pressure–Lowering TherapyFurther Reading* Effects of intensive blood-pressure control in type 2 diabetes mellitus* A Randomized Trial of Intensive versus Standard Blood-Pressure ControlSensible Medicine is 100% reader-supported. If you appreciate our work, consider becoming a free or paid subscriber. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.sensible-med.com/subscribe

Howie and Harlan are joined by cardiologist Ali Rahimi, the founder of ALYKA Health, which uses a personalized mobile app to help patients manage their heart health between doctor's visits. Harlan discusses new developments in GLP-1 obesity drugs, including untested microdose treatments; Howie reviews a landmark study investigating whether broad prostate cancer screening saves lives. Show notes: GLP-1 Drugs "Microdosing aims to extend the lifespan of the GLP-1 compounding market" NIH: Regulatory Framework for Compounded Preparations Health & Veritas Episode 140: Lee Schwamm: Smarter Healthcare Systems With AI "FDA takes on GLP-1 compounding boom with warnings about misleading marketing" "Should You Microdose GLP-1 Drugs?" "How microdosing GLP-1 drugs became a longevity 'craze'" "Bidding war between Pfizer, Novo Nordisk for obesity startup Metsera escalates" "Trump Negotiating Deal With Ozempic Maker to Sell Some Weight-Loss Drugs for $149""Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment" "How Ozempic's Maker Lost Its Shine After Creating a Wonder Drug" Ali Rahimi ALYKA Health Harlan Krumholz and Ali Rahimi, "Financial Barriers to Health Care and Outcomes After Acute Myocardial Infarction" "Why High Blood Pressure Matters to Your Health" Building a Better Delivery System: A New Engineering/Health Care Partnership NIH: The 21st Century Cures Act New Evidence on Prostate Cancer Screening and Breast Cancer Treatment National Cancer Institute: Cancer Stat Facts: Prostate Cancer" U.S. Preventive Services Task Force: Prostate Cancer: Screening" "The pros and cons of PSA tests for prostate cancer for midlife and older men" "Share on European Study of Prostate Cancer Screening — 23-Year Follow-up" "Early Detection of Prostate Cancer — Time to Fish or Cut Bait" "Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer" "Omission of Chest-Wall Irradiation after Mastectomy for Breast Cancer" In the Yale School of Management's MBA for Executives program, you'll get a full MBA education in 22 months while applying new skills to your organization in real time. Yale's Executive Master of Public Health offers a rigorous public health education for working professionals, with the flexibility of evening online classes alongside three on-campus trainings. Email Howie and Harlan comments or questions.  

Howie and Harlan are joined by cardiologist Ali Rahimi, the founder of ALYKA Health, which uses a personalized mobile app to help patients manage their heart health between doctor's visits. Harlan discusses new developments in GLP-1 obesity drugs, including untested microdose treatments; Howie reviews a landmark study investigating whether broad prostate cancer screening saves lives. Show notes: GLP-1 Drugs "Microdosing aims to extend the lifespan of the GLP-1 compounding market" NIH: Regulatory Framework for Compounded Preparations Health & Veritas Episode 140: Lee Schwamm: Smarter Healthcare Systems With AI "FDA takes on GLP-1 compounding boom with warnings about misleading marketing" "Should You Microdose GLP-1 Drugs?" "How microdosing GLP-1 drugs became a longevity 'craze'" "Bidding war between Pfizer, Novo Nordisk for obesity startup Metsera escalates" "Trump Negotiating Deal With Ozempic Maker to Sell Some Weight-Loss Drugs for $149""Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment" "How Ozempic's Maker Lost Its Shine After Creating a Wonder Drug" Ali Rahimi ALYKA Health Harlan Krumholz and Ali Rahimi, "Financial Barriers to Health Care and Outcomes After Acute Myocardial Infarction" "Why High Blood Pressure Matters to Your Health" Building a Better Delivery System: A New Engineering/Health Care Partnership NIH: The 21st Century Cures Act New Evidence on Prostate Cancer Screening and Breast Cancer Treatment National Cancer Institute: Cancer Stat Facts: Prostate Cancer" U.S. Preventive Services Task Force: Prostate Cancer: Screening" "The pros and cons of PSA tests for prostate cancer for midlife and older men" "Share on European Study of Prostate Cancer Screening — 23-Year Follow-up" "Early Detection of Prostate Cancer — Time to Fish or Cut Bait" "Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer" "Omission of Chest-Wall Irradiation after Mastectomy for Breast Cancer" In the Yale School of Management's MBA for Executives program, you'll get a full MBA education in 22 months while applying new skills to your organization in real time. Yale's Executive Master of Public Health offers a rigorous public health education for working professionals, with the flexibility of evening online classes alongside three on-campus trainings. Email Howie and Harlan comments or questions.  

"[When] a lot of men think about prostate exams, they immediately think of the glove going on the hand of the physician, and they immediately clench. But really try to talk with them and discuss with them what some of the benefits are of understanding early detection. Even just having those conversations with their providers so that they understand what the risk and benefits are of having screening. And then educate patients on what a prostate-specific antigen (PSA) and digital rectal exam (DRE) actually are—how it happens, what it shows, and what the necessary benefits of those are," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer screening, early detection, and disparities. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by October 31, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to prostate screening, early detection, and disparities. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ Episode 149: Health Disparities and Barriers in Metastatic Castration-Sensitive Prostate Cancer ONS Voice articles: Gender-Affirming Hormones May Lower PSA and Delay Prostate Cancer Diagnosis in Transgender Women Healthy Lifestyles Reduce Prostate Cancer Mortality in Patients With Genetic Risk Hispanic Patients Are at Higher Risk for Aggressive Prostate Cancer but Less Likely to Get Treatment Leveling State-Level Tax Policies May Increase Equality in Cancer Screening and Mortality Rates Most Cancer Screening Guidelines Don't Disclose Potential Harms ONS book: Understanding Genomic and Hereditary Cancer Risk: A Handbook for Oncology Nurses ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing article: Barriers and Solutions to Cancer Screening in Gender Minority Populations Oncology Nursing Forum articles: Disparities in Cancer Screening in Sexual and Gender Minority Populations: A Secondary Analysis of Behavioral Risk Factor Surveillance System Data Symptom Experiences Among Individuals With Prostate Cancer and Their Partners: Influence of Sociodemographic and Cancer Characteristics Other ONS resources: Genomics and Precision Oncology Learning Library ONS Biomarker Database (refine by prostate cancer) American Cancer Society prostate cancer early detection, diagnosis, and staging page National Institutes of Health prostate cancer screening page U.S. Preventive Services Task Force prostate cancer screening recommendation statement To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "The recommendations are men [aged] 45 who are at high risk, including African American men and men who have a first-degree relative who has been diagnosed with prostate cancer younger than 65 should go through screening. And men aged 40 at an even higher risk, these are the men that have that one first-degree relative who has had prostate cancer before 65. Screening includes the PSA blood test and a digital exam. Those are the screening recommendations, although they are a little bit controversial." TS 3:42 "You still see PSAs and DREs as the first line because they're easier for primary care providers to perform. ... Those are typically covered by insurance, so they still play that role in screening. But with the advent of MRIs and biomarkers, these have really helped refine that screening process and determine treatment options for our patients. Again, those patients who may be at a bit of a higher risk could go for an MRI or have biomarkers completed. Or if they're on that verge with their Gleason score, instead of doing a biopsy, they may send the patient for an MRI or do biomarkers for that patient. ... These updated technologies put [patients] a little bit more at ease that someone's watching what's going on, and they don't have to have anything invasive done to see where they're at with their staging." TS 4:35 "Disparities in screening access exist based on race, socioeconomic status, gender identity, education, and geography. It's really hard in rural areas to get primary care providers or urologists who can actually see these patients, [and] sometimes in urban areas. So socioeconomic status can affect that, but also where a person lives. African American men with lower incomes and people in rural areas face the greatest barriers to receiving screening. It's also important to encourage anyone with a prostate to be screened and offer gender-neutral settings for patients to feel comfortable." TS 7:50 "I think a lot of men feel like if they have no symptoms, they don't have prostate cancer ... so a lot of patients may put off screening because they feel fine, [they] haven't had any urinary symptoms, it doesn't run in their family. ...With prostate cancer, there usually are not symptoms that a patient's having—they may have some urinary issues or some pain—but it's not very frequent that they have that. So, just making sure our patients understand that even though they're not feeling something, it doesn't mean there's not something else going on there." TS 12:53 "Prostate cancer found at an early age can be very curable, so it's really important for men to have those conversations with their providers about the risk and benefits of screening. And anyone that we can help along the way to be able to have those conversations, I think is a great thing for oncology nurses to do." TS 15:44

Host: Darryl S. Chutka, M.D. Guest: Daniel M. Frendl, M.D., Ph.D. If your practice includes middle age and older men, you've very likely diagnosed prostate cancer. It's the most diagnosed non-skin cancer in men in the U.S. Its incidence rises with age, with a median age of around 66 years. When found early, prostate cancer is very treatable, and in most cases, curable. Prostate specific antigen, or PSA is very effective in detecting early prostate cancer, but its use has been controversial due to the risk of overdiagnosis and overtreatment. What are the current recommendations for prostate cancer screening with PSA? What's the role of the digital rectal exam? How should we be using the PSA and what other tests are available for prostate cancer screening? The topic for this podcast is “Prostate Cancer Screening” and I'll be asking these questions to my guest, Daniel M. Frendl, M.D., Ph.D., a urologist at the Arizona campus of the Mayo Clinic. Tune in this Thursday for our next episode on "Prostate Cancer" releasing October 30, 2025. Connect with us and learn more here: https://ce.mayo.edu/online-education/content/mayo-clinic-podcasts 

This week Bobbi Conner talks with MUSC's Dr. Eric Wallen about prostate cancer screening.

In this Healthed lecture, the experts will answer questions about changes to the prostate cancer screening guidelines including the updated risk: benefit profile for PSA testing, who should have this test and how PSA test results should now be interpreted and managed. In addition, this case-based discussion will cover the practical application of the new draft guidelines on prostate cancer screening that are likely to be endorsed and become standard of care in the near future.See omnystudio.com/listener for privacy information.

What is the role of PSA for early detection, and how does hormone therapy affect cancer patients? These are questions we dig into in this episode. https://bit.ly/4lC0ZUdIn This Episode:01:32 - Road Trip-South Carolina & Shout Halellujah Potato Salad02:38 - Fighting For Your Life Is Boring - Andrew Reynolds04:44 - Prostate Cancer - Risks and Treatment09:46 - Why Was Biden's Prostate Cancer Detected So Late?14:52 - Signs and Symptoms of Prostate Cancer16:08 - Gleason Scoring for Prostate Cancer Grade19:18 - Hormone Therapy - Androgen Deprivation33:27 - Prostate Cancer and Partners36:21 - OutroAbout 1 in 8 men will be diagnosed with prostate cancer during their lifetime. Prostate cancer is the second-leading cause of cancer death in American men, behind lung cancer. Learn signs and symptoms, the role of PSA (prostate-specific antigen) for early detection and monitoring, how androgen-blocking therapy works, and how it affects patients and their partners.Support the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org

Last month, former President Joe Biden announced that he had been diagnosed with an aggressive form of prostate cancer. The news sparked a larger conversation about what exactly the best practices are to screen for prostate cancer. Turns out, it's more complicated than it might seem. Host Ira Flatow is joined by oncologist Matthew Cooperberg and statistician Andrew Vickers, who studies prostate cancer screening, to help unpack those complexities.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Prostate cancer screening isn't just clinical—it's personal. Especially when headlines make it political.In this episode Tracy breaks down the buzz around President Joe Biden's recent prostate cancer diagnosis—and uses the moment to teach, clarify, and contextualize what it really means to screen for prostate cancer in 2025.As a former Urology PA, Tracy brings her clinical experience and clear communication to an often-misunderstood topic. She walks through:What the prostate does and how PSA testing worksWhat elevates PSA levels (that isn't cancer)Why BPH complicates the pictureWhat Gleason scores tell us about cancer aggressivenessCurrent USPSTF and AUA guidelines for prostate cancer screeningHow shared decision-making, not headlines, should guide patient careThis episode is a reminder to return to nuance and individualize care—especially when the world is watching.

What do Diddy's “black hotel bag” with many secrets, President Joe Biden's prostate cancer diagnosis, LaVar Ball's diabetes amputations, and a surgeon accidentally removing a woman's healthy kidney have in common? They're all making headlines - and we're breaking them down, no sugarcoating, no medical mumbo jumbo! We're dissecting these medical headlines with a dose of evidence-based facts and the kind of practical advice you'll actually remember when it counts.By the way, have you heard of “Ozempic teeth”? Don't worry, we'll break that down too, plus a whole lot more. And just because it's Memorial Day, I'm giving you my top 5 tips for a healthy summer with a twist! Let's get into it together, laugh a little, and leave a lot smarter.This podcast is intended to be informational only.  It is not a medical consultation, nor is it personalized medical advice.  For medical advice, please consult your physician.#HealthHappyLifePodcast #DrFrita #MedicalMondays #MedicineInTheNewsHere are a few helpful resources to help on your journey to wellness:▶️ Subscribe so you will never miss a YouTube video.

AP correspondent Ben Thomas reports former President Biden's office is providing more information about his health screenings.

Hour 3 for 5/19/25 Drew discussed prostate cancer screening with Dr. Umang Gautam (1:00). Topics: frozen treatment (10:58), early testing (12:43), caller: cancer survivor (13:39), caller: my husband's health story (19:17), health foods (21:15), and caller: I had cancer (24:57). Then, Fr. Burke Masters discussed Pete Rose's Hall of Fame ban lifted (31:54). Topics: ethics in baseball (35:46), caller: I think he should be in the Hall of Fame (39:00), and caller: I think there is a lot of hypocrisy in sports (42:34), and morality in sports (45:46).

A polygenic risk score significantly improved prostate cancer detection beyond PSA testing, identifying more treatable and aggressive cancers in high-risk men. New WHO guidelines aim to reduce global meningitis deaths by standardizing early diagnosis, treatment, and care across settings. GLP-1 receptor agonists and SGLT2 inhibitors were linked to reduced Alzheimer's risk, with GLP-1s showing the most consistent neuroprotective effects in recent studies. Lastly, breast cancer mortality was 47% higher among Black women living in disadvantaged neighborhoods, underscoring the impact of social determinants on survival.

Masood Moghul, MBBS, a urologist and Research Fellow at the Royal Marsden Hospital and Institute of Cancer Research in London shared findings from a study investigating a mobile, targeted, case-finding approach to prostate cancer detection with 3,379 patients. Moghul told the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco how the study addressed health inequalities and barriers to accessing health care that affect prostate cancer in high-risk underserved groups.

Masood Moghul, MBBS, a urologist and research fellow at the Royal Marsden Hospital and Institute of Cancer Research in London, UK, discussed his group’s findings from the Man Van study investigating a mobile, targeted, case-finding approach to prostate cancer detection with 3,379 patients conducted in Greater London. Moghul told the 2025 ASCO Genitourinary Cancers Symposium in San Francisco how the study had addressed health inequalities and barriers to accessing health care that affect prostate cancer in high-risk underserved groups.

In this edition of The Naked Scientists: A new screening test for prostate cancer that can, the inventors claim, accurately catch 96% of cases, and early. Also, why you might want to eschew artificial sweeteners: a new study suggests they can accelerate arterial disease. And, scientists show that turtles can sense magnetic fields to find their way around... Like this podcast? Please help us by supporting the Naked Scientists

LOUNGE LIZARDS PRESENTED BY FABRICA 5 - Visit Fabrica005.com and use code LIZARDPOD at checkout for 10% off THE ENTIRE STORE! Free worldwide shipping from Miami on all orders over $125. See website for more information and terms.Recorded at Ten86 Cigars in Hawthorne, New Jersey, the lizards pair Arturo Fuente Don Carlos The Man with Redbreast Iberian Series Lustau Edition. The guys read a listener email about prostate cancer and detecting it early, they enjoy some Whiskey ASMR, they discuss Car Smoking Accessories and Chef Ricky gives an update on his new tower.Plus: Preferred Hygrometers and More Generational Smoking BansJoin the Lounge Lizards for a weekly discussion on all things cigars (both Cuban and non-Cuban), whiskey, food, travel, life and work. This is your formal invitation to join us in a relaxing discussion amongst friends and become a card-carrying Lounge Lizard yourself. This is not your typical cigar podcast. We're a group of friends who love sharing cigars, whiskey and a good laugh.website/merch/rating archive: loungelizardspod.comemail: hello@loungelizardspod.com to join the conversation and be featured on an upcoming episode!instagram: @loungelizardspodGizmo HQ: LizardGizmo.com

Prostate cancer screening is an essential aspect of men's health, and current advancements in testing are making early detection more precise than ever before. While the PSA (Prostate-Specific Antigen) test has long been the standard, it has limitations and may lead to unnecessary biopsies. The new EpiSwitch PSE test helps differentiate between high and low prostate cancer risks. With an impressive 94% accuracy rate, the EpiSwitch PSE test empowers patients and physicians to make informed decisions. In this episode, Dr. Garrett Pohlman explores the latest innovations in prostate cancer screening, focusing on the EpiSwitch PSE blood test.  Stay tuned to discover the benefits of the new EpiSwitch PSE test and learn how precision medicine is reshaping prostate cancer management for men. Disclaimer: The Prostate Health Podcast is for informational purposes only. Nothing in this podcast should be construed as medical advice. By listening to the podcast, no physician-patient relationship has been formed. For more information and counseling, you must contact your personal physician or urologist with questions about your unique situation. Show Highlights: What are the limitations of the PSA test? How the EpiSwitch PSE test can predict the risk of prostate cancer with 94% accuracy How prostate cancer biomarkers help to identify the likelihood of prostate cancer  How the EpiSwitch PSE test can provide a more accurate assessment of prostate cancer risk How the EpiSwitch PSE test can help men avoid unnecessary biopsies The clinical applications of the EpiSwitch PSE test and how it can be used alongside a standard PSA test to improve accuracy How the EpiSwitch PSE test requires just two milliliters of blood  How even patients who have undergone recent BPH procedures or are on 5-alpha reductase inhibitors can use the EpiSwitch PSE test Why the EpiSwitch PSE test is more accurate than PSA testing Why men need to be aware of their PSA numbers and consider additional testing if they have an elevated PSA Pertinent disclosures for this episode:  Dr. Garrett Pohlman is a Consultant for Oxford BioDynamics Links:  Follow Dr. Pohlman on Twitter and Instagram - @gpohlmanmd  Get your free What To Expect Guide (or find the link on our podcast website)   Join our Facebook group  Follow Dr. Pohlman on Twitter and Instagram  Go to the Prostate Health Academy to sign up.  You can access Dr. Pohlman's free mini webinar, where he discusses his top three tips to promote men's prostate health, longevity, and quality of life here.  

Jonathan Shoag, MD, discusses his innovative prostate cancer research aiming to better understand the impact of PSA screening and his groundbreaking work on the genetics of aging. About Jonathan Shoag, MD Learn more about the University Hospitals Research & Education Institute Follow Us on Social:      

Guidelines for breast cancer screening have been gradually shifting, and urologists say prostate cancer screening guidelines also need to be updated. Our house doctor, Mike Simon speaks with host Steven Webb about the importance of early screening for prostate cancer.

Prostate cancer is the second most common cancer in men, behind only skin cancer. In recent years, advances in screening, surgery and radiation treatment have improved outcomes and led to an increase in what is known as active surveillance after the initial diagnosis of prostate cancer. “The goal of active surveillance is to maximize the quality of life for patients while at the same time preserving the quantity of life,” said Akshay Sood, MD, a James urologic oncologist who specializes in treating prostate and bladder cancer. Dr. Sood explained the importance of screening, the prostate-specific antigen (PSA) test and what it means, the Gleason score and how these numbers help oncologists determine when to treat patients. He also discussed what's involved in prostate-cancer surgery and radiation treatments, and advances in both of these areas. Dr. Sood is also one of the leaders of the James Multidisciplinary Prostate Cancer Clinic and he described the benefits to patients of this all-in-one clinic that includes a large team of prostate cancer experts. “Unfortunately, there are no symptoms, which is why screening is so important,” Dr. Sood said of prostate cancer. PSA screening should begin at the age of 45 for most men. African American men (who have a higher rate of prostate cancer) and those with a family history of prostate and other types of cancers should begin their yearly PSA screenings at 40. “A PSA level below 4 is considered normal, while a score above 4 is abnormal,” Dr. Sood said. A high score will often lead to a biopsy to determine of the patient has cancer and, if they do, where it ranks on the Gleason scale and the genetic mutation causing the cancer.

Broadcast from KSQD, Santa Cruz on 10-10-2024: Dr. Dawn announces Medicare's new list of over 200 drugs available for $2 per 30-day supply, covering a wide range of medications. She discusses a new urine test called ExoDx for prostate cancer screening, which can help avoid unnecessary biopsies in the "gray zone" of elevated PSA levels. The doctor addresses a listener's question about Klebsiella pneumoniae found in a nasal swab, explaining colonization versus infection and the risks of unnecessary antibiotic use. Dr. Dawn explores the reliability of QuantiFERON TB tests, suggesting potential false positives and the importance of retesting with different antigen tubes. She discusses orthostatic hypotension in older adults, offering practical tips like squeezing a firm ball before standing up and proper standing techniques to prevent falls. The doctor explains the importance of vitamin A for vegans, highlighting potential BCMO1 genetic variations that may affect beta-carotene conversion and recommending blood tests. Dr. Dawn addresses a question about elevated bilirubin levels post-gallbladder removal, discussing possible causes and diagnostic procedures like MRI and ERCP.

Broadcast from KSQD, Santa Cruz on 10-10-2024: Dr. Dawn announces Medicare's new list of over 200 drugs available for $2 per 30-day supply, covering a wide range of medications. She discusses a new urine test called ExoDx for prostate cancer screening, which can help avoid unnecessary biopsies in the "gray zone" of elevated PSA levels. The doctor addresses a listener's question about Klebsiella pneumoniae found in a nasal swab, explaining colonization versus infection and the risks of unnecessary antibiotic use. Dr. Dawn explores the reliability of QuantiFERON TB tests, suggesting potential false positives and the importance of retesting with different antigen tubes. She discusses orthostatic hypotension in older adults, offering practical tips like squeezing a firm ball before standing up and proper standing techniques to prevent falls. The doctor explains the importance of vitamin A for vegans, highlighting potential BCMO1 genetic variations that may affect beta-carotene conversion and recommending blood tests. Dr. Dawn addresses a question about elevated bilirubin levels post-gallbladder removal, discussing possible causes and diagnostic procedures like MRI and ERCP.

Welcome to the Hot Topics podcast from NB Medical with Dr Neal Tucker. In this episode, we have three exciting new papers. Firstly, in the BMJ a network meta-analysis on acute migraine treatments - can the new GEPANTs drugs beat existing therapies? Secondly, a paper in NEJM does screening for prostate cancer using MRI actually help? Finally in the BJGP can first contact physio be better than a GP appointment? Listen on! ReferencesBMJ Acute migraine therapiesNEJM Prostate cancer screening with MRIBJGP First contact physio in GPwww.nbmedical.com/podcast

Requested by KP listeners! An update on a patient from the previous prostate cancer episode and a deep dive into the history of prostate cancer screening. References: Kazuto, I. et al. Screening for prostate cancer: History, evidence, controversies and future perspectives toward individualized screening. International journal of urology. 2019; 26(10). doi:10.1111/iju.14039 Albertsen PC. The Evolving Paradigm of Prostate Cancer Screening. JAMA Netw Open. 2019;2(8):e198392. doi:10.1001/jamanetworkopen.2019.8392 USPSTF Final Recommendation Statement: Prostate Cancer Screening, 2018. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening Wei JT, Barocas D, Carlsson S, et al. Early detection of prostate cancer: AUA/SUO guideline part I: prostate cancer screening. J Urol. 2023;210(1):45-53.

House Doctor Peter Lin brought us his reflections on a new medical test. It can help identity genetic markers that are linked the most aggressive cases of prostate cancer.

Hello and welcome to HBR News where we talk about the news of the week! This week we discuss what might be some good news such as advancements in prostate cancer screenings, Prince William opens a clinic for men, and more!

Editor's Summary by Anne Rentoumis Cappola, MD, ScM, Associate Editor of JAMA, the Journal of the American Medical Association, for the May 7, 2024, issue.

This week, in recognition of Colorectal Cancer Awareness Month, we engage in a conversation with Dr. Robert Zaiden, MD, FACP, focusing on ctDNA testing in GI cancers and his team's contributions.Dr. Zaiden, a seasoned medical oncologist in Jacksonville, FL, specializing in GI/GU tumors, stands as one of the founding members of Baptist MD Anderson. His active participation and leadership in various committees, including the role of Physician-in-Chief and Head of Cancer Medicine ad interim, underscore his commitment to optimizing patient care. Serving as the current director of the GI Tumor board, he has been instrumental in the rapid growth of Baptist MD Anderson.With a wealth of experience, Dr. Zaiden has been a Principal Investigator or Sub-Investigator in over 20 clinical trials. Recognized with prestigious awards such as Physician of the Year and Teaching and Excellence awards, he is also the Medical Director of Infusion Centers at BMDA.Before joining Baptist Medical Center in 2015, Dr. Zaiden contributed to the Hematology/Oncology faculty at the University of Florida in Jacksonville. During his tenure at UF, he received the Outstanding Resident Teacher award and was consistently voted Exemplary Faculty Teacher for five consecutive years. Beyond his professional accomplishments, Dr. Zaiden actively promoted Colorectal and Prostate Cancer Screening awareness to underserved communities, delivering cancer awareness talks at the YMCA. He proudly received the WeCare Patient's Choice award in 2023.This episode is sponsored by Walgreens. Our expert oncology-specialized pharmacy team is here for you. Our patients are at the heart of what we do and our pharmacists offer expert and compassionate support throughout each patient's unique cancer journey. Let's work together to care for the whole patient. Click here to find a Walgreens oncology-specialized pharmacist near you.

How did the COVID-19 pandemic affect clinical outcomes in patients with diabetes? Find out about this and more in today's PV Roundup podcast.

Do you know that prostate cancer is the second most prevalent cancer in American men, following skin cancer? A new diagnosis of prostate cancer occurs every two minutes. We are delighted to partner with Oxford Biodynamics for today's episode with Dr. Robert Heaton, who joins us to discuss a ground-breaking new prostate cancer screening test that predicts the risk of prostate cancer with 94% accuracy, using a simple blood test. Dr. Heaton is a board-certified pathologist. He completed his medical training at Georgetown University and then spent the next twenty years in the US Navy. After finishing his residency training in pathology, Dr. Heaton became the Director of Laboratory and Clinical Support Services for the National Naval Medical Center before joining various hospital pathology labs and life sciences companies. He is currently the Laboratory Medical Director for Oxford Biodynamics at their CLIA-certified clinical lab in Maryland, where he oversees the clinical operations of their liquid biopsy blood tests. In today's episode, we dive into the details of the innovative EpiSwitch Prostate Screening test, known as the PSE, designed to confirm the presence of prostate cancer, whether symptoms are present or not. This technological advancement is a game-changer! It empowers urologists by providing a precise tool to assess whether a patient should undergo a biopsy or opt for continued monitoring. Stay tuned to learn how this simple yet powerful tool streamlines the screening process for men struggling with prostate cancer. Disclaimer: The Prostate Health Podcast is for informational purposes only. Nothing in this podcast should be construed as medical advice. By listening to the podcast, no physician-patient relationship has been formed. For more information and counseling, you must contact your personal physician or urologist with questions about your unique situation.   Show Highlights: At what age should men start getting checked for prostate cancer?  What the screening for prostate cancer typically entails The importance of establishing a baseline to monitor how PSA changes over time Dr. Heaton dives into the details of the EpiSwitch PSA test How men can access the EpiSwitch PSA test Dr. Heaton discusses the accuracy of the EpiSwitch PSA test What is the expected turnaround time for the EpiSwitch PSC test results? Dr. Heaton explains the role of the Epi Switch PSA test in different scenarios The revolutionary EpiSwitch Prostate Screening test has remarkable accuracy in predicting prostate cancer risk through a simple blood test. It holds immense promise for men battling prostate cancer by providing urologists with a precise diagnostic tool and offering a streamlined approach for patients facing the complexities of prostate cancer. Links: Follow Dr. Pohlman on Twitter and Instagram - @gpohlmanmd Get your free What To Expect Guide (or find the link on our podcast website)   Join our Facebook group  Follow Dr. Pohlman on Twitter and Instagram  Go to the Prostate Health Academy to sign up.  You can access Dr. Pohlman's free mini webinar, where he discusses his top three tips to promote men's prostate health, longevity, and quality of life here. Oxford BioDynamics: Website LinkedIn  Facebook Twitter: @oxbiodynamics and #OBD Instagram: @oxbiodynamics YouTube: @oxfordbiodynamics PSE: Website LinkedIn Facebook Twitter: (@94percent_com) Instagram: (@get_the_pse)

Navigating guidelines, parsing through the PSA, Survivorship, & More! Become a pro when addressing prostate cancer! We tackle the nuances surrounding screening for this all-to-common cancer and discuss important considerations in survivorship with our guest Dr. Petar Bajic (Twitter: @PBajicMD, Instagram: @the.sexdoc) of Cleveland Clinic! You're IN for a good time listening to this episode! Claim free CME for this episode at curbsiders.vcuhealth.org! Episodes | Subscribe | Spotify | Swag! | Top Picks | Mailing List | askcurbsiders@gmail.com | Free CME! Show Segments ●      Intro, disclaimer, guest bio ●      Guest one-liner ●      Case from Kashlak ●      Epidemiology of Prostate Cancer ●      Screening Basics ●      What is the PSA? ●      Next Steps After Elevated PSA ●      Thresholds and techniques for biopsy ●      Free PSA, Other testing modalities, Prostate MRI ●      Active Surveillance Nuts and Bolts ●      Survivorship ●      Take home points, Outro Credits ●      Producer,Writer, Show Notes,  Infographic, Cover Art: Beth Garbitelli MD ●      Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP, Beth Garbitelli MD ●      Reviewer: Sai S Achi, MD MBA ●      Showrunner: Matthew Watto MD, FACP; Paul Williams MD, FACP ●      Technical Production: PodPaste ●      Guest: Dr. Petar Bajic MD Sponsor: Better Help  Learn more and save 10% off your first month ast betterhelp.com/curb Sponsor: Birch Living  Birch is giving $400 off all mattresses and 2 free eco-rest pillows at birchliving.com/curb Sponsor: Hello Fresh Go to hellofresh.com/curb18 and use code curb18 for 18 free meals plus free shipping.  Sponsor: Pattern Life Visit patternlife.com/curbsiders to request your free physician disability insurance quote. Full Transcript HERE